Exact Mass: 868.4265

Exact Mass Matches: 868.4265

Found 117 metabolites which its exact mass value is equals to given mass value 868.4265, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Fevicordin B 2-gentiobioside

6-(5,13-Dihydroxy-1,6,11,15-tetramethyl-17-oxo-4-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-trien-14-yl)-6-hydroxy-2-methyl-5-oxoheptan-2-yl acetic acid

C43H64O18 (868.4092)


Fevicordin B 2-gentiobioside is found in fruits. Fevicordin B 2-gentiobioside is a constituent of Cyclanthera pedata (achoccha). Constituent of Cyclanthera pedata (achoccha). Fevicordin B 2-gentiobioside is found in fruits.

   

C-Telopeptide

4-amino-4-({5-amino-1-[(1-{[1-({2-carboxy-1-[({[({1-carboxy-4-[(diaminomethylidene)amino]butyl}carbamoyl)methyl]carbamoyl}methyl)carbamoyl]ethyl}carbamoyl)-2-(1H-imidazol-5-yl)ethyl]carbamoyl}ethyl)carbamoyl]pentyl}carbamoyl)butanoic acid

C34H56N14O13 (868.4151)


   

PGP(a-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

[(2S)-3-({[(2R)-2-{[(5R,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-3-[(12-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(a-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one 12-methyltetradecanoyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/a-15:0)

[(2S)-3-({[(2R)-3-{[(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-2-[(12-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/a-15:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/a-15:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of 12-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(a-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

[(2S)-3-({[(2R)-2-{[(5S,6E,8Z,11Z,13E,15R)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-3-[(12-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(a-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one 12-methyltetradecanoyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/a-15:0)

[(2S)-3-({[(2R)-3-{[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-2-[(12-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/a-15:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/a-15:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 12-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(a-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

[(2S)-3-({[(2R)-2-{[(5R,6R,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-3-[(12-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(a-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one 12-methyltetradecanoyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/a-15:0)

[(2S)-3-({[(2R)-3-{[(5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-2-[(12-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/a-15:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/a-15:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 12-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-14:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2S)-2-hydroxy-3-({hydroxy[(2R)-3-[(12-methyltridecanoyl)oxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C40H70O16P2 (868.4139)


PGP(i-14:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-14:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-14:0)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-2-[(12-methyltridecanoyl)oxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C40H70O16P2 (868.4139)


PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-14:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-14:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

[(2S)-3-({[(2R)-2-{[(5R,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-3-[(13-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(i-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one 13-methyltetradecanoyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-15:0)

[(2S)-3-({[(2R)-3-{[(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-2-[(13-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-15:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-15:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of 13-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

[(2S)-3-({[(2R)-2-{[(5S,6E,8Z,11Z,13E,15R)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-3-[(13-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(i-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one 13-methyltetradecanoyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-15:0)

[(2S)-3-({[(2R)-3-{[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-2-[(13-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-15:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-15:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 13-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

[(2S)-3-({[(2R)-2-{[(5R,6R,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-3-[(13-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(i-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one 13-methyltetradecanoyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-15:0)

[(2S)-3-({[(2R)-3-{[(5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-2-[(13-methyltetradecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C41H74O15P2 (868.4503)


PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-15:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-15:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 13-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PI(16:2(9Z,12Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

[(2R)-3-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-2-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(16:2(9Z,12Z)/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(16:2(9Z,12Z)/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of 9Z,12Z-hexadecenoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(20:4(6E,8Z,11Z,14Z)+=O(5)/16:2(9Z,12Z))

[(2R)-2-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-3-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(20:4(6E,8Z,11Z,14Z)+=O(5)/16:2(9Z,12Z)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(20:4(6E,8Z,11Z,14Z)+=O(5)/16:2(9Z,12Z)), in particular, consists of one chain of 5-oxo-eicosatetraenoyl at the C-1 position and one chain of 9Z,12Z-hexadecenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(16:2(9Z,12Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

[(2R)-3-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-2-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(16:2(9Z,12Z)/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(16:2(9Z,12Z)/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of 9Z,12Z-hexadecenoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(20:4(5Z,8Z,11Z,13E)+=O(15)/16:2(9Z,12Z))

[(2R)-2-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-3-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(20:4(5Z,8Z,11Z,13E)+=O(15)/16:2(9Z,12Z)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(20:4(5Z,8Z,11Z,13E)+=O(15)/16:2(9Z,12Z)), in particular, consists of one chain of 15-oxo-eicosatetraenoyl at the C-1 position and one chain of 9Z,12Z-hexadecenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

[(2R)-3-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-2-{[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of 9Z,12Z-hexadecenoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/16:2(9Z,12Z))

[(2R)-2-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-3-{[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/16:2(9Z,12Z)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/16:2(9Z,12Z)), in particular, consists of one chain of 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of 9Z,12Z-hexadecenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

[(2R)-3-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-2-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of 9Z,12Z-hexadecenoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/16:2(9Z,12Z))

[(2R)-2-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-3-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/16:2(9Z,12Z)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/16:2(9Z,12Z)), in particular, consists of one chain of 15-hydroxyleicosapentaenyl at the C-1 position and one chain of 9Z,12Z-hexadecenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(16:2(9Z,12Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

[(2R)-3-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-2-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(16:2(9Z,12Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(16:2(9Z,12Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of 9Z,12Z-hexadecenoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/16:2(9Z,12Z))

[(2R)-2-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-3-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/16:2(9Z,12Z)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/16:2(9Z,12Z)), in particular, consists of one chain of 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of 9Z,12Z-hexadecenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(16:2(9Z,12Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

[(2R)-3-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-2-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(16:2(9Z,12Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(16:2(9Z,12Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of 9Z,12Z-hexadecenoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   

PI(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/16:2(9Z,12Z))

[(2R)-2-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]-3-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C45H73O14P (868.4738)


PI(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/16:2(9Z,12Z)) is an oxidized phosphatidylinositol (PI). Phosphatidylinositols are important lipids, both as a key membrane constituent and as a participant in essential metabolic processes, both directly and via a number of metabolites. Phosphatidylinositols are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to inositol (hexahydroxycyclohexane). Phosphatidylinositols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PI(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/16:2(9Z,12Z)), in particular, consists of one chain of 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of 9Z,12Z-hexadecenoyl at the C-2 position. The inositol group that is part of every phosphatidylinositol lipid is covalently linked to the phosphate group that acts as a bridge to the lipid tail. In most organisms, the stereochemical form of this inositol is myo-D-inositol (with one axial hydroxyl in position 2 with the remainder equatorial), although other forms can be found in certain plant phosphatidylinositols. Phosphatidylinositol is especially abundant in brain tissue, where it can amount to 10\\% of the phospholipids, but it is present in all tissues and cell types. There is usually less of it than of phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. In animal tissues, phosphatidylinositol is the primary source of the arachidonic acid required for biosynthesis of eicosanoids, including prostaglandins, via the action of the enzyme phospholipase A2. Phosphatidylinositol can be phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated by a specific kinase. Seven different isomers are known, but the most important in both quantitative and biological terms are phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PIs composed exclusively of non-phosphorylated inositol exhibit a net charge of -1 at physiological pH. Molecules with phosphorylated inositol (such as PIP, PIP2, PIP3, etc.) are termed polyphosphoinositides. The polyphosphoinositides are important intracellular transducers of signals emanating from the plasma membrane. The synthesis of PI involves CDP-activated 1,2-diacylglycerol condensation with myo-inositol.

   
   

Cryptostigmin I

Cryptostigmin I

C44H68O17 (868.4456)


   

3-((3-Malonyl)Xyl)-28-Glu Bayogenin

3-((3-Malonyl)Xyl)-28-Glu Bayogenin

C44H68O17 (868.4456)


   

neoruscogenin 1-O-[O-beta-D-glucopyranosyl-(1-->3)-O-alpha-L-rhamnopyranosyl-(1-->2)-alpha-L-arabinopyranoside]|ruscin|ruscoponticoside D|spirosta-5,25(27)-diene-1beta,3beta-diol 1-O-[beta-D-glucopyranosyl-(1->3)-O-alpha-L-rhamnopyranosyl-(1->2)-O-alpha-L-arabinopyranoside]

neoruscogenin 1-O-[O-beta-D-glucopyranosyl-(1-->3)-O-alpha-L-rhamnopyranosyl-(1-->2)-alpha-L-arabinopyranoside]|ruscin|ruscoponticoside D|spirosta-5,25(27)-diene-1beta,3beta-diol 1-O-[beta-D-glucopyranosyl-(1->3)-O-alpha-L-rhamnopyranosyl-(1->2)-O-alpha-L-arabinopyranoside]

C44H68O17 (868.4456)


   
   

(3beta,25R)-3-hydroxyspirost-5-en-7-one-3-O-alpha-L-arabinofuranosyl-(1->4)-[alpha-L-rhamnopyranosyl-(1->2)]-beta-D-glucopyranoside|(3beta,25R)-7-oxospirost-5-en-3-yl alpha-L-arabinofuranosyl-(1-->4)-[6-deoxy-alpha-L-mannopyranosyl-(1--> 2)]-beta-D-glucopyranoside|kingianoside K

(3beta,25R)-3-hydroxyspirost-5-en-7-one-3-O-alpha-L-arabinofuranosyl-(1->4)-[alpha-L-rhamnopyranosyl-(1->2)]-beta-D-glucopyranoside|(3beta,25R)-7-oxospirost-5-en-3-yl alpha-L-arabinofuranosyl-(1-->4)-[6-deoxy-alpha-L-mannopyranosyl-(1--> 2)]-beta-D-glucopyranoside|kingianoside K

C44H68O17 (868.4456)


   

acodontasteroside A

acodontasteroside A

C40H68O18S (868.4126)


   
   

30,32-dihydroxymycalolide A

30,32-dihydroxymycalolide A

C45H64N4O13 (868.447)


   

3beta,16beta,17alpha-trihydroxycholest-5-en-22-one 16-O-[O-(2-E-cinnamoyl-beta-D-xylopyranosyl)-(1->3)-2-O-acetyl-alpha-L-arabinopyranoside]

3beta,16beta,17alpha-trihydroxycholest-5-en-22-one 16-O-[O-(2-E-cinnamoyl-beta-D-xylopyranosyl)-(1->3)-2-O-acetyl-alpha-L-arabinopyranoside]

C48H68O14 (868.4609)


   

26-O-beta-D-glucopyranosyl-furosta-5,20(22), 25(27)-triene-1beta,3beta,26-triol 1-O-[alpha-L-rhamnopyranosyl-(1?2)-O-alpha-L-arabinopyranoside]|26-O-beta-D-glucopyranosyl-furosta-5,20(22),25(27)-triene-1beta,3beta,26-triol 1-O-[alpha-L-rhamnopyranosyl-(1->2)-O-alpha-L-arabinopyranoside]|26-O-beta-D-glucopyranosylfurosta-5,20(22),25(27)-triene-1beta,3beta,26-triol 1-O-[O-alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyranoside]|26-O-beta-D-glucopyranosylfurosta-5,20(22),25(27)-triene-1beta,3beta,26-triol-1-O-alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyranoside|furosta-5,20(22),25(27)-trien-1beta,3beta,26-triol 1-O-[alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyranoside] 26-O-beta-D-glucopyranoside

26-O-beta-D-glucopyranosyl-furosta-5,20(22), 25(27)-triene-1beta,3beta,26-triol 1-O-[alpha-L-rhamnopyranosyl-(1?2)-O-alpha-L-arabinopyranoside]|26-O-beta-D-glucopyranosyl-furosta-5,20(22),25(27)-triene-1beta,3beta,26-triol 1-O-[alpha-L-rhamnopyranosyl-(1->2)-O-alpha-L-arabinopyranoside]|26-O-beta-D-glucopyranosylfurosta-5,20(22),25(27)-triene-1beta,3beta,26-triol 1-O-[O-alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyranoside]|26-O-beta-D-glucopyranosylfurosta-5,20(22),25(27)-triene-1beta,3beta,26-triol-1-O-alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyranoside|furosta-5,20(22),25(27)-trien-1beta,3beta,26-triol 1-O-[alpha-L-rhamnopyranosyl-(1->2)-alpha-L-arabinopyranoside] 26-O-beta-D-glucopyranoside

C44H68O17 (868.4456)


   

C44H68O17_(1beta,3alpha,9xi,14xi)-1-Hydroxyspirosta-5,25(27)-dien-3-yl beta-D-glucopyranosyl-(1->3)-6-deoxy-alpha-L-mannopyranosyl-(1->2)-(3xi)-alpha-D-threo-pentopyranoside

NCGC00347384-02_C44H68O17_(1beta,3alpha,9xi,14xi)-1-Hydroxyspirosta-5,25(27)-dien-3-yl beta-D-glucopyranosyl-(1->3)-6-deoxy-alpha-L-mannopyranosyl-(1->2)-(3xi)-alpha-D-threo-pentopyranoside

C44H68O17 (868.4456)


   

Fevicordin B 2-gentiobioside

6-(5,13-dihydroxy-1,6,11,15-tetramethyl-17-oxo-4-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-trien-14-yl)-6-hydroxy-2-methyl-5-oxoheptan-2-yl acetate

C43H64O18 (868.4092)


   

(25S)-26-O-[(3S)-3-hydroxy-3-methylglutaryl]-22,25-epoxy-furost-5-en-3beta-yl O-alpha-L-rhamnopyranosyl-(1-2)-beta-D-glucopyranoside

(25S)-26-O-[(3S)-3-hydroxy-3-methylglutaryl]-22,25-epoxy-furost-5-en-3beta-yl O-alpha-L-rhamnopyranosyl-(1-2)-beta-D-glucopyranoside

C44H68O17 (868.4456)


   

Anemarrhenasaponin Ia

Anemarrhenasaponin Ia

C48H68O14 (868.4609)


   

Substance P (5-11) trifluoroacetate salt

Substance P (5-11) trifluoroacetate salt

C41H60N10O9S (868.4265)


   
   

PGP(a-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

PGP(a-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C41H74O15P2 (868.4503)


   

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/a-15:0)

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/a-15:0)

C41H74O15P2 (868.4503)


   

PGP(a-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

PGP(a-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C41H74O15P2 (868.4503)


   

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/a-15:0)

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/a-15:0)

C41H74O15P2 (868.4503)


   

PGP(a-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

PGP(a-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C41H74O15P2 (868.4503)


   

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/a-15:0)

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/a-15:0)

C41H74O15P2 (868.4503)


   

PGP(i-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

PGP(i-15:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C41H74O15P2 (868.4503)


   

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-15:0)

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-15:0)

C41H74O15P2 (868.4503)


   

PGP(i-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

PGP(i-15:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C41H74O15P2 (868.4503)


   

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-15:0)

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-15:0)

C41H74O15P2 (868.4503)


   

PGP(i-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

PGP(i-15:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C41H74O15P2 (868.4503)


   

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-15:0)

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-15:0)

C41H74O15P2 (868.4503)


   

PGP(i-14:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PGP(i-14:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C40H70O16P2 (868.4139)


   

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-14:0)

PGP(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/i-14:0)

C40H70O16P2 (868.4139)


   

PI(16:2(9Z,12Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

PI(16:2(9Z,12Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

C45H73O14P (868.4738)


   

PI(20:4(6E,8Z,11Z,14Z)+=O(5)/16:2(9Z,12Z))

PI(20:4(6E,8Z,11Z,14Z)+=O(5)/16:2(9Z,12Z))

C45H73O14P (868.4738)


   

PI(16:2(9Z,12Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

PI(16:2(9Z,12Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

C45H73O14P (868.4738)


   

PI(20:4(5Z,8Z,11Z,13E)+=O(15)/16:2(9Z,12Z))

PI(20:4(5Z,8Z,11Z,13E)+=O(15)/16:2(9Z,12Z))

C45H73O14P (868.4738)


   

PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C45H73O14P (868.4738)


   

PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/16:2(9Z,12Z))

PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/16:2(9Z,12Z))

C45H73O14P (868.4738)


   

PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

PI(16:2(9Z,12Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C45H73O14P (868.4738)


   

PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/16:2(9Z,12Z))

PI(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/16:2(9Z,12Z))

C45H73O14P (868.4738)


   

PI(16:2(9Z,12Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

PI(16:2(9Z,12Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C45H73O14P (868.4738)


   

PI(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/16:2(9Z,12Z))

PI(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/16:2(9Z,12Z))

C45H73O14P (868.4738)


   

PI(16:2(9Z,12Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

PI(16:2(9Z,12Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C45H73O14P (868.4738)


   

PI(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/16:2(9Z,12Z))

PI(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/16:2(9Z,12Z))

C45H73O14P (868.4738)


   

Biexcisusin B, (rel)-

Biexcisusin B, (rel)-

C48H68O14 (868.4609)


A natural product found in Isodon excisus.

   

Peptidoglycan(N-acetyl-D-glucosamine)

Peptidoglycan(N-acetyl-D-glucosamine)

C34H60N8O18 (868.4025)


   

[3-[[3-[[3-[(7Z,9Z,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] hexadecanoate

[3-[[3-[[3-[(7Z,9Z,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] hexadecanoate

C41H74O15P2 (868.4503)


   

[3-[[3-[[3-[(4E,7Z)-hexadeca-4,7-dienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (4E,7Z)-hexadeca-4,7-dienoate

[3-[[3-[[3-[(4E,7Z)-hexadeca-4,7-dienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (4E,7Z)-hexadeca-4,7-dienoate

C41H74O15P2 (868.4503)


   

[3-[[3-[[3-[(9Z,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (Z)-hexadec-7-enoate

[3-[[3-[[3-[(9Z,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (Z)-hexadec-7-enoate

C41H74O15P2 (868.4503)


   

[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropoxy]phosphoryl]oxypropyl] (11E,13E,15E)-octadeca-11,13,15-trienoate

[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropoxy]phosphoryl]oxypropyl] (11E,13E,15E)-octadeca-11,13,15-trienoate

C41H74O15P2 (868.4503)


   

[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[hydroxy-(2-hydroxy-3-tetradecanoyloxypropoxy)phosphoryl]oxypropoxy]phosphoryl]oxypropyl] (9Z,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[hydroxy-(2-hydroxy-3-tetradecanoyloxypropoxy)phosphoryl]oxypropoxy]phosphoryl]oxypropyl] (9Z,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C41H74O15P2 (868.4503)


   
   
   

PI P-16:1/20:6;O2

PI P-16:1/20:6;O2

C45H73O14P (868.4738)


   
   
   
   

PI 22:4/13:4;O2

PI 22:4/13:4;O2

C44H69O15P (868.4374)


   

PI 22:5/13:3;O2

PI 22:5/13:3;O2

C44H69O15P (868.4374)


   

PI 22:6/12:3;O3

PI 22:6/12:3;O3

C43H65O16P (868.401)


   
   
   
   

Tau protein (592-597), human (TFA)

Tau protein (592-597), human (TFA)

C36H63F3N10O11 (868.463)


Tau protein (592-597), human TFA is a peptide fragment of human Tau protein. The dysfunction of Tau protein is involved in neurodegeneration and dementia[1].

   

6-(2,7-dihydroxy-3a,6,9b,11a-tetramethyl-10-oxo-8-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,5h,11h-cyclopenta[a]phenanthren-1-yl)-6-hydroxy-2-methyl-5-oxoheptan-2-yl acetate

6-(2,7-dihydroxy-3a,6,9b,11a-tetramethyl-10-oxo-8-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,5h,11h-cyclopenta[a]phenanthren-1-yl)-6-hydroxy-2-methyl-5-oxoheptan-2-yl acetate

C43H64O18 (868.4092)


   

2-{[4,5-dihydroxy-2-({16-hydroxy-7,9,13-trimethyl-6-[3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-6,18-dien-14-yl}oxy)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

2-{[4,5-dihydroxy-2-({16-hydroxy-7,9,13-trimethyl-6-[3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-6,18-dien-14-yl}oxy)oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C44H68O17 (868.4456)


   

(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5s,6r)-4-hydroxy-5-{[(2s,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

(1r,2s,3as,3br,5ar,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,4s,5s,6r)-4-hydroxy-5-{[(2s,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C44H68O17 (868.4456)


   

(2s,3r,4s,5r)-2-{[(2s,3r,4s,5s)-2-{[(1s,2s,3as,3br,7s,9ar,9bs,11as)-1,7-dihydroxy-9a,11a-dimethyl-1-[(2s)-6-methyl-3-oxoheptan-2-yl]-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-3-(acetyloxy)-5-hydroxyoxan-4-yl]oxy}-4,5-dihydroxyoxan-3-yl (2e)-3-phenylprop-2-enoate

(2s,3r,4s,5r)-2-{[(2s,3r,4s,5s)-2-{[(1s,2s,3as,3br,7s,9ar,9bs,11as)-1,7-dihydroxy-9a,11a-dimethyl-1-[(2s)-6-methyl-3-oxoheptan-2-yl]-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-3-(acetyloxy)-5-hydroxyoxan-4-yl]oxy}-4,5-dihydroxyoxan-3-yl (2e)-3-phenylprop-2-enoate

C48H68O14 (868.4609)


   

(2r,3s,4r,5r,6s)-2-{[(2r,3s,4s,5r,6r)-2-{[(2s,3r,5s)-4,5-dihydroxy-2-[(1'r,2s,4'r,7'r,8's,9'r,13's,14's,16'r)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-14'-oloxy]oxan-3-yl]oxy}-3,5-dihydroxy-6-methyloxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3s,4r,5r,6s)-2-{[(2r,3s,4s,5r,6r)-2-{[(2s,3r,5s)-4,5-dihydroxy-2-[(1'r,2s,4'r,7'r,8's,9'r,13's,14's,16'r)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-14'-oloxy]oxan-3-yl]oxy}-3,5-dihydroxy-6-methyloxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C44H68O17 (868.4456)


   

2-[({3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-12-[2-(methylsulfanyl)ethyl]-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-5-carbamimidamidopentanoic acid

2-[({3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-12-[2-(methylsulfanyl)ethyl]-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-5-carbamimidamidopentanoic acid

C41H60N10O9S (868.4265)


   

n-[(1e,3r,4r,5s,6r,9s,10s)-4,6-dihydroxy-11-[(10s,11r,13e,16s,20s,21r,22s,24e)-16-hydroxy-10,22-dimethoxy-11,21-dimethyl-12,18-dioxo-3,7,19,27-tetraoxa-29,30,31-triazatetracyclo[24.2.1.1²,⁵.1⁶,⁹]hentriaconta-1(28),2(31),4,6(30),8,13,24,26(29)-octaen-20-yl]-10-methoxy-3,5,9-trimethylundec-1-en-1-yl]-n-methylformamide

n-[(1e,3r,4r,5s,6r,9s,10s)-4,6-dihydroxy-11-[(10s,11r,13e,16s,20s,21r,22s,24e)-16-hydroxy-10,22-dimethoxy-11,21-dimethyl-12,18-dioxo-3,7,19,27-tetraoxa-29,30,31-triazatetracyclo[24.2.1.1²,⁵.1⁶,⁹]hentriaconta-1(28),2(31),4,6(30),8,13,24,26(29)-octaen-20-yl]-10-methoxy-3,5,9-trimethylundec-1-en-1-yl]-n-methylformamide

C45H64N4O13 (868.447)


   

(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-5-{[(2s,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-20'-one

(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,16's)-16'-{[(2r,3r,4s,5s,6r)-5-{[(2s,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-20'-one

C44H68O17 (868.4456)


   

(1s,1's,3s,3's,4r,4'r,6s,6's,8s,8's,9r,9'r,10s,10's,11s,11's,13r,13'r,17s)-6,6',11'-tris(acetyloxy)-3,3',8,8'-tetrahydroxy-5,5,5',5',9,9'-hexamethyl-15'-oxo-18-oxaspiro[pentacyclo[11.6.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁹]icosane-17,14'-tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan]-14(19)-en-11-yl acetate

(1s,1's,3s,3's,4r,4'r,6s,6's,8s,8's,9r,9'r,10s,10's,11s,11's,13r,13'r,17s)-6,6',11'-tris(acetyloxy)-3,3',8,8'-tetrahydroxy-5,5,5',5',9,9'-hexamethyl-15'-oxo-18-oxaspiro[pentacyclo[11.6.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁹]icosane-17,14'-tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan]-14(19)-en-11-yl acetate

C48H68O14 (868.4609)


   

[(1r,2r,4s,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-4,18-dimethyl-5-oxo-14-phenyl-17-{[(2e)-3-phenylprop-2-enoyl]oxy}-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadecan-8-yl]methyl hexadecanoate

[(1r,2r,4s,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-4,18-dimethyl-5-oxo-14-phenyl-17-{[(2e)-3-phenylprop-2-enoyl]oxy}-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadecan-8-yl]methyl hexadecanoate

C52H68O11 (868.4761)


   

(6r)-6-[(1r,2r,3ar,3bs,9br,11ar)-2,7-dihydroxy-3a,6,9b,11a-tetramethyl-10-oxo-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,5h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxoheptan-2-yl acetate

(6r)-6-[(1r,2r,3ar,3bs,9br,11ar)-2,7-dihydroxy-3a,6,9b,11a-tetramethyl-10-oxo-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,5h,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxoheptan-2-yl acetate

C43H64O18 (868.4092)


   

(2s)-2-({[(3s,6s,9s,12s,15r)-3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-12-[2-(methylsulfanyl)ethyl]-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-5-carbamimidamidopentanoic acid

(2s)-2-({[(3s,6s,9s,12s,15r)-3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-12-[2-(methylsulfanyl)ethyl]-8-oxo-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-5-carbamimidamidopentanoic acid

C41H60N10O9S (868.4265)


   

[(1r,3r,3as,3bs,5s,5ar,6r,7s,9as,9br,11ar)-1-[(2r,3e,5r)-5-({[(2r,3r,4s,5s)-3-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-5-[(1r)-1,2-dihydroxyethyl]-4-hydroxyoxolan-2-yl]oxy}methyl)-6-methylhept-3-en-2-yl]-3,3b,6,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid

[(1r,3r,3as,3bs,5s,5ar,6r,7s,9as,9br,11ar)-1-[(2r,3e,5r)-5-({[(2r,3r,4s,5s)-3-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-5-[(1r)-1,2-dihydroxyethyl]-4-hydroxyoxolan-2-yl]oxy}methyl)-6-methylhept-3-en-2-yl]-3,3b,6,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-yl]oxidanesulfonic acid

C40H68O18S (868.4126)


   

n-(4,6-dihydroxy-11-{16-hydroxy-10,22-dimethoxy-11,21-dimethyl-12,18-dioxo-3,7,19,27-tetraoxa-29,30,31-triazatetracyclo[24.2.1.1²,⁵.1⁶,⁹]hentriaconta-1(28),2(31),4,6(30),8,13,24,26(29)-octaen-20-yl}-10-methoxy-3,5,9-trimethylundec-1-en-1-yl)-n-methylformamide

n-(4,6-dihydroxy-11-{16-hydroxy-10,22-dimethoxy-11,21-dimethyl-12,18-dioxo-3,7,19,27-tetraoxa-29,30,31-triazatetracyclo[24.2.1.1²,⁵.1⁶,⁹]hentriaconta-1(28),2(31),4,6(30),8,13,24,26(29)-octaen-20-yl}-10-methoxy-3,5,9-trimethylundec-1-en-1-yl)-n-methylformamide

C45H64N4O13 (868.447)


   

(2s,3r,4r,5r,6s)-2-{[(2s,3r,4s,5s)-4,5-dihydroxy-2-{[(1s,2s,4s,8s,9s,12s,13r,14r,16r)-16-hydroxy-7,9,13-trimethyl-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-6,18-dien-14-yl]oxy}oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

(2s,3r,4r,5r,6s)-2-{[(2s,3r,4s,5s)-4,5-dihydroxy-2-{[(1s,2s,4s,8s,9s,12s,13r,14r,16r)-16-hydroxy-7,9,13-trimethyl-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-6,18-dien-14-yl]oxy}oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C44H68O17 (868.4456)


   

2-({2-[(4,5-dihydroxy-2-{7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy}oxan-3-yl)oxy]-3,5-dihydroxy-6-methyloxan-4-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

2-({2-[(4,5-dihydroxy-2-{7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy}oxan-3-yl)oxy]-3,5-dihydroxy-6-methyloxan-4-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C44H68O17 (868.4456)


   

(2s,3r,4r,5r,6s)-2-[2-chloro-6-(6-chlorododecyl)-3-(6-chloropentadecyl)-5-hydroxy-4-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]phenoxy]-6-methyloxane-3,4,5-triol

(2s,3r,4r,5r,6s)-2-[2-chloro-6-(6-chlorododecyl)-3-(6-chloropentadecyl)-5-hydroxy-4-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]phenoxy]-6-methyloxane-3,4,5-triol

C44H75Cl3O10 (868.4426)


   

(1-{5-[({3-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-5-(1,2-dihydroxyethyl)-4-hydroxyoxolan-2-yl}oxy)methyl]-6-methylhept-3-en-2-yl}-3,3b,6,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-yl)oxidanesulfonic acid

(1-{5-[({3-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-5-(1,2-dihydroxyethyl)-4-hydroxyoxolan-2-yl}oxy)methyl]-6-methylhept-3-en-2-yl}-3,3b,6,7-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-yl)oxidanesulfonic acid

C40H68O18S (868.4126)


   

(2s,3r,4s,5s,6r)-2-{[(2s,3r,4r,5s,6s)-2-{[(2s,3r,4s,5s)-4,5-dihydroxy-2-[(1's,2r,2's,4's,7's,8'r,9's,12's,13'r,14'r,16'r)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy]oxan-3-yl]oxy}-3,5-dihydroxy-6-methyloxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{[(2s,3r,4r,5s,6s)-2-{[(2s,3r,4s,5s)-4,5-dihydroxy-2-[(1's,2r,2's,4's,7's,8'r,9's,12's,13'r,14'r,16'r)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy]oxan-3-yl]oxy}-3,5-dihydroxy-6-methyloxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C44H68O17 (868.4456)


   

16'-[(5-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl)oxy]-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-20'-one

16'-[(5-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-4-hydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl)oxy]-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-20'-one

C44H68O17 (868.4456)


   

(2r)-2-[(3s,6s,9s,15s,19s,23e,25e,28r,29r,30r)-5,8,11,14,17,19,22-heptahydroxy-6-[(r)-hydroxy(c-hydroxycarbonimidoyl)methyl]-15-(hydroxymethyl)-3-isopropyl-28-methoxy-29-methyl-2-oxo-30-[(2s)-pentan-2-yl]-1-oxa-4,7,10,13,16,21-hexaazacyclotriaconta-4,7,10,13,16,21,23,25-octaen-9-yl]propanimidic acid

(2r)-2-[(3s,6s,9s,15s,19s,23e,25e,28r,29r,30r)-5,8,11,14,17,19,22-heptahydroxy-6-[(r)-hydroxy(c-hydroxycarbonimidoyl)methyl]-15-(hydroxymethyl)-3-isopropyl-28-methoxy-29-methyl-2-oxo-30-[(2s)-pentan-2-yl]-1-oxa-4,7,10,13,16,21-hexaazacyclotriaconta-4,7,10,13,16,21,23,25-octaen-9-yl]propanimidic acid

C39H64N8O14 (868.4542)


   

(1r,2s,3as,3bs,5ar,7s,9as,9br,11ar)-3a-hydroxy-7-{[(2r,4s,5s,6r)-4-hydroxy-5-{[(2s,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

(1r,2s,3as,3bs,5ar,7s,9as,9br,11ar)-3a-hydroxy-7-{[(2r,4s,5s,6r)-4-hydroxy-5-{[(2s,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C44H68O17 (868.4456)


   

3a-hydroxy-7-({4-hydroxy-5-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

3a-hydroxy-7-({4-hydroxy-5-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C44H68O17 (868.4456)


   

(1r)-1-[(2r,3s,4r,5r)-5-{[(3s,6r)-6-[(1r,3r,3as,3bs,4r,5r,5as,7s,9as,9br,11ar)-3,3b,4,5,7-pentahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-2-methylheptan-3-yl]oxy}-3-hydroxy-4-{[(2s,3r,4s,5s,6r)-4-hydroxy-3,5-dimethoxy-6-methyloxan-2-yl]oxy}oxolan-2-yl]ethoxysulfonic acid

(1r)-1-[(2r,3s,4r,5r)-5-{[(3s,6r)-6-[(1r,3r,3as,3bs,4r,5r,5as,7s,9as,9br,11ar)-3,3b,4,5,7-pentahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]-2-methylheptan-3-yl]oxy}-3-hydroxy-4-{[(2s,3r,4s,5s,6r)-4-hydroxy-3,5-dimethoxy-6-methyloxan-2-yl]oxy}oxolan-2-yl]ethoxysulfonic acid

C41H72O17S (868.449)


   

2-{5,8,11,14,17,19,22-heptahydroxy-6-[hydroxy(c-hydroxycarbonimidoyl)methyl]-15-(hydroxymethyl)-3-isopropyl-28-methoxy-29-methyl-2-oxo-30-(pentan-2-yl)-1-oxa-4,7,10,13,16,21-hexaazacyclotriaconta-4,7,10,13,16,21,23,25-octaen-9-yl}propanimidic acid

2-{5,8,11,14,17,19,22-heptahydroxy-6-[hydroxy(c-hydroxycarbonimidoyl)methyl]-15-(hydroxymethyl)-3-isopropyl-28-methoxy-29-methyl-2-oxo-30-(pentan-2-yl)-1-oxa-4,7,10,13,16,21-hexaazacyclotriaconta-4,7,10,13,16,21,23,25-octaen-9-yl}propanimidic acid

C39H64N8O14 (868.4542)